Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/106611
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial |
Author: | Smith, D. Smith, M. Sweeney, C. Elfiky, A. Logothetis, C. Corn, P. Vogelzang, N. Small, E. Harzstark, A. Gordon, M. Vaishampayan, U. Haas, N. Spira, A. Lara, P. Lin, C. Srinivas, S. Sella, A. Schöffski, P. Scheffold, C. Weitzman, A. et al. |
Citation: | Journal of Clinical Oncology, 2013; 31(4):412-419 |
Publisher: | American Society of Clincal Oncology |
Issue Date: | 2013 |
ISSN: | 0732-183X 1527-7755 |
Statement of Responsibility: | David C. Smith, Matthew R. Smith, Christopher Sweeney, Aymen A. Elfiky, Christopher Logothetis, Paul G. Corn, Nicholas J. Vogelzang, Eric J. Small, Andrea L. Harzstark, Michael S. Gordon, Ulka N. Vaishampayan, Naomi B. Haas, Alexander I. Spira, Primo N. Lara Jr, Chia-Chi Lin, Sandy Srinivas, Avishay Sella, Patrick Schöffski, Christian Scheffold, Aaron L. Weitzman, and Maha Hussain |
Abstract: | Abstract not available |
Keywords: | Biomarkers, Tumor |
Rights: | © 2012 by American Society of Clinical Oncology |
DOI: | 10.1200/JCO.2012.45.0494 |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.